CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of "Hold" by Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have earned an average rating of "Hold" from the seventeen ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $69.53.

A number of research analysts have weighed in on the company. Wall Street Zen upgraded CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. HC Wainwright reissued a "buy" rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. JMP Securities reiterated a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, May 21st. Finally, The Goldman Sachs Group decreased their price objective on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th.

CRISPR Therapeutics Trading Down 0.4%

Shares of CRSP opened at $44.25 on Friday. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of -9.79 and a beta of 1.75. CRISPR Therapeutics has a 12 month low of $30.04 and a 12 month high of $63.68. The firm has a fifty day simple moving average of $38.61 and a 200 day simple moving average of $40.67.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. The business's revenue was up 71.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.43) EPS. As a group, research analysts predict that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the sale, the insider now owns 6,068 shares in the company, valued at $218,083.92. The trade was a 39.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Voya Investment Management LLC lifted its position in shares of CRISPR Therapeutics by 60.2% during the 1st quarter. Voya Investment Management LLC now owns 13,870 shares of the company's stock valued at $472,000 after acquiring an additional 5,210 shares during the period. Bayforest Capital Ltd acquired a new position in CRISPR Therapeutics in the first quarter valued at about $423,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in CRISPR Therapeutics by 182.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company's stock valued at $66,452,000 after purchasing an additional 1,262,560 shares in the last quarter. Woodline Partners LP lifted its position in CRISPR Therapeutics by 34.3% during the first quarter. Woodline Partners LP now owns 136,483 shares of the company's stock worth $4,645,000 after purchasing an additional 34,883 shares during the period. Finally, Millennium Management LLC grew its stake in CRISPR Therapeutics by 6,769.1% during the first quarter. Millennium Management LLC now owns 583,733 shares of the company's stock worth $19,864,000 after buying an additional 575,235 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.